Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS long-term extension study of bitopertin in EPP or XLP
NL-OMON58801Phase 3Recruiting
- Sponsor
- Disc Medicine
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Disc Medicine. Primary endpoint: Safety and tolerability of bitopertin. Started Jun 2026; status: recruiting.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NL-OMON58801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58801.